ストックスクリーナーアプリを入手
4.70
6.00%
-0.30
アフターアワーズ：
4.67
-0.03
-0.64%
前日終値:
$5.00
開ける：
$4.9
24時間の取引高:
211.83K
Relative Volume:
0.33
時価総額：
$293.26M
収益：
-
当期純損益:
$-238.77M
株価収益率:
-0.1753
EPS:
-26.808
ネットキャッシュフロー:
$-216.62M
1週間 パフォーマンス:
-12.80%
1か月 パフォーマンス:
+25.33%
6か月 パフォーマンス:
-62.64%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$4.645
$5.0306
1週間の範囲:
$4.645
$5.65
52週間の値動き範囲:
$3.18
$13.50
Alumis Inc Stock (ALMS) Company Profile
ALMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
4.70 | 293.26M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-30 | 開始されました | Oppenheimer | Outperform |
| 2024-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2024-10-17 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 開始されました | Guggenheim | Buy |
| 2024-07-23 | 開始されました | Leerink Partners | Outperform |
| 2024-07-23 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Alumis Inc (ALMS) 最新ニュース
Revised merger terms boost ACELYRIN stake in Alumis deal By Investing.com - Investing.com South Africa
Alumis And Acelyrin Announce Amended Merger Agreement - marketscreener.com
Alumis, ACELYRIN amend proposed merger pact - Seeking Alpha
Alumis Raises Share Consideration for Acelyrin Acquisition - marketscreener.com
ACELYRIN, INC. Amends Merger Agreement with Alumis - TipRanks
ACELYRIN and Alumis Announce Revised Merger Agreement Enhancing Stockholder Ownership and Value - Nasdaq
Alumis and ACELYRIN Announce Amended Merger Agreement - The Manila Times
Alumis Secures Major Immunology Merger: $737M Cash Runway Stretches to 2027, 62% Shareholders Back Deal - Stock Titan
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - MarketScreener
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday - Benzinga
3 Biopharmaceutical Stocks Bucking the Sell-Off - MarketBeat
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alumis: Biotech's Stock Gains >100% In A MonthBut Risk Of Failure Is High (NASDAQ:ALMS) - Seeking Alpha
Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
Alumis Reaches US$465m Market Cap Benefiting Insider Stock Buying - simplywall.st
Insider Buying: Alumis Independent Director Bought US$130k Of Shares - Yahoo
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - The Manila Times
Alumis and ACELYRIN announce definitive merger plan By Investing.com - Investing.com South Africa
Alumis and ACELYRIN announce definitive merger plan - Investing.com Australia
Major Biopharma Merger: Alumis and ACELYRIN Unite with $737M War Chest for Immune Disease Breakthroughs - Stock Titan
Simulations Plus Posts Better-Than-Expected Results, Joins Savers Value Village, MarketAxess Holdings And Other Big Stocks Moving Higher On Friday - Benzinga
Alumis Inc. CEO Martin Babler buys $100,732 in company stock By Investing.com - Investing.com Australia
Alumis Inc. director Alan Colowick buys $129,544 in stock By Investing.com - Investing.com Australia
Top Executives Make Bold Moves with Alumis Inc. Stock Purchases! - TipRanks
Alumis Inc. CEO Martin Babler buys $100,732 in company stock - Investing.com
Alumis Inc. director Alan Colowick buys $129,544 in stock - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders - The Malaysian Reserve
Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday - Benzinga
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Alumis Inc. (NASDAQ:ALMS) Stock Holdings Increased by Charles Schwab Investment Management Inc. - Defense World
Q2 Earnings Forecast for Alumis Issued By Leerink Partnrs - MarketBeat
The week in pharma: action, reaction and insight – week to March 28 - The Pharma Letter
Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera Biosimilars - insights.citeline.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders - The Malaysian Reserve
Last-minute suitor nearly upends Alumis, Acelyrin merger - The Business Journals
Amphenol (APH): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – SLRN - Bluefield Daily Telegraph
Alumis and Kaken Pharma announce collaboration worth $140 M for dermatology treatment in Japan - BioSpectrum Asia
Alumis Inc. Reports 2024 Results and Strategic Merger - TipRanks
Strategic Partnerships and Financial Projections Bolster Buy Rating for Alumis Inc. - TipRanks
Alumis stock holds $15 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com South Africa
Alumis stock holds $15 target, Buy rating at H.C. Wainwright - Investing.com
Q1 Earnings Forecast for Alumis Issued By Leerink Partnrs - Defense World
Alumis sees uptick as Kaken locks Japan rights for dermatology asset - FirstWord Pharma
Alumis and Kaken Pharmaceutical Announce Collaboration and - GlobeNewswire
Alumis rises on licensing deal with Japan’s Kaken - MSN
Acelyrin Sees Stock Price Rise Amid Rights Plan - Los Angeles Business Journal
What's Going On With Alumis Shares Tuesday? - Benzinga
Alumis Inc (ALMS) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):